Overview: CD23 Immunohistochemistry TestIntroduction: The CD23 Immunohistochemistry Test detects CD23 protein to diagnose lymphomas, causing lymph node swelling or fever. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected lymphomas, particularly chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Other Names: CD23 IHC Assay, Lymphoma CD23 Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD23 testing began in the 1990s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD23 to diagnose lymphomas, guides treatment, and evaluates patients with lymph node swelling or fever.
Test Parameters: 1. CD23 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fever, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fever, fatigue, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD23 in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for CLL/SLL diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD23 staining suggests CLL/SLL, guiding chemotherapy or immunotherapy. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD5 IHC, flow cytometry, or IGVH mutation testing to confirm CLL/SLL diagnosis.
Test Limitations: Not specific to CLL/SLL; other lymphomas may express CD23. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
